Skip to main content

Table 2 Case-case ORs of tumor characteristics by age among premenopausal cases in Carolina Breast Cancer Study phases I–III (n = 2373)

From: Breast cancer biologic and etiologic heterogeneity by young age and menopausal status in the Carolina Breast Cancer Study: a case-control study

  Age <40 years Age ≥40 years (reference)
Tumor characteristic n (%) OR (95 % CI) n (%)
Mean age (±SD) 34.8 (±3.7)   45.4 (±3.5)
Stage
 In situ 35 (5.4) 0.98 (0.65–1.49) 125 (7.5)
 Stage I 163 (25.3) 1.0 573 (34.5)
 Stage II 340 (52.7) 1.74 (1.40–2.16) 687 (41.4)
 Stage III 84 (13.0) 1.34 (0.99–1.82) 220 (13.3)
 Stage IV 23 (3.6) 1.47 (0.88–2.46) 55 (3.3)
 Missing 19   51
Subtypea
 Luminal 106 (52.0) 1.0 283 (65.2)
 Basal-like 51 (25.0) 1.87 (1.22–2.84) 73 (16.8)
 HER2 18 (8.8) 1.72 (0.91–3.23) 28 (6.5)
 Unclassified 29 (14.2) 1.55 (0.93–2.58) 50 (11.5)
 Missing 109   286
ER status
 Negative 270 (44.9) 1.0 515 (33.4)
 Positive 332 (55.1) 0.62 (0.51–0.75) 1028 (66.6)
 Missingb 62   168
PR status
 Negative 302 (53.6) 1.0 544 (37.6)
 Positive 261 (46.4) 0.52 (0.43–0.63) 903 (62.4)
 Missingb 101   264
HER2 statusa
 Negative 194 (77.0) 1.0 447 (82.3)
 Positive 58 (23.0) 1.39 (0.96–2.01) 96 (17.7)
 Missing 61   177
Histologic gradec
 Well-differentiated/moderate differentiation 89 (21.3) 1.0 268 (25.6)
 Poor differentiation 328 (78.7) 1.27 (0.97–1.66) 779 (74.4)
 Missingb 82   238
Nuclear gradec
 Slight/moderate pleomorphism 174 (41.2) 1.0 557 (52.2)
 Marked pleomorphism 248 (58.8) 1.55 (1.24–1.95) 511 (47.8)
 Missingc 77   217
Node status
 Negative 329 (53.4) 1.0 907 (58.4)
 Positive 287 (46.6) 1.23 (1.02–1.48) 645 (41.6)
 Missingb 48   159
Tumor size
 ≤ 2 cm 233 (38.4) 1.0 749 (48.8)
 > 2 cm 373 (61.6) 1.53 (1.26–1.85) 786 (51.2)
 Missingb 58   176
  1. ER estrogen receptor, HER2 human epidermal growth factor receptor 2, PR progesterone receptor
  2. aExcludes phase III cases
  3. bMissing data due to ongoing data collection for phase III cases
  4. cExcludes phase II cases